Prolonged continuous infusion of low-dose rIL-2.

Documenti analoghi

• Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
  di: Gratama, J W, et al.
  Pubblicazione: (1993)
• Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma
  di: Geertsen, P F, et al.
  Pubblicazione: (2004)
• Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma.
  di: Janssen, R. A., et al.
  Pubblicazione: (1992)
• Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.
  di: Martens, A., et al.
  Pubblicazione: (1993)
• Treatment of Diabetic Coma with Continuous Low-dose Infusion of Insulin
  di: Page, M. McB., et al.
  Pubblicazione: (1974)